Identification | Back Directory | [Name]
nitrofurantoin sodium | [CAS]
54-87-5 | [Synonyms]
Ivadantin Einecs 200-216-7 Sodium furadantin nitrofurantoin sodium Nitrofurandantoin sodium NITROFURANTOIN, SODIUM SALT Hydantoin, 1-((5-nitrofurfurylidene)amino)-, sodium salt 1-[(5-nitrofurfurylidene)amino]imidazolidine-2,4-dione, sodium salt 1-[[(5-Nitro-2-furanyl)methylene]amino]-2-sodiooxyimidazolidin-4-one 1-[[(5-Nitro-2-furanyl)methylene]amino]-2-sodiooxyimidazolidine-4-one 2,4-Imidazolidinedione, 1-(((5-nitro-2-furanyl)methylene)amino)-, sodium salt (9ci) | [EINECS(EC#)]
200-216-7 | [Molecular Formula]
C8H7N4NaO5 | [MDL Number]
MFCD01722779 | [MOL File]
54-87-5.mol | [Molecular Weight]
262.16 |
Hazard Information | Back Directory | [Uses]
Nitrofurantoin sodium is a potent and orally active antibacterial agent. Nitrofurantoin sodium acts as an antibiotic. Nitrofurantoin sodium can be used for the study of urinary tract infections (UTIs), including cystitis and kidney infections[1][2]. | [Brand name]
Ivadantin (Procter & Gamble). | [in vivo]
1.19 Nitrofurantoin pharmacokinetic effects in SD Rats[4]. Parameters | 10 mg/kg p.o. | 2 mg/kg i.v. | AUC0-720 (μg/mL?min) | 306 | | AUC0-120 (μg/mL?min) | | 90.3 | AUC0-∞ (μg/mL?min) | 344 | 91.5 | Cmax (μg/mL) | 1.01 | | CL/F or CL (ml/min/kg) | 31.0 | 22.7 | t1/2 (min) | 166 | 23.6 | Bioavailability (%) | 60.1 | | |
| [References]
[1] Huttner A, et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015 Sep;70(9):2456-64. DOI:10.1093/jac/dkv147 [2] Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:198-202. DOI:10.1111/j.1469-0691.2007.01852.x [3] Linus Sandegren, et al. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother. 2008 Sep;62(3):495-503. DOI:10.1093/jac/dkn222 [4] Xiaodong Wang, et al. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos. 2007 Feb;35(2):268-74. DOI:10.1124/dmd.106.011684 |
|
|